Current therapies available to treat and heal ocular surface injuries and periocular burns are frequently inadequate, costly, and labor intensive. To address these limitations, we have employed a flexible, semitransparent ocular wound chamber (OWC) to provide protection as well as a watertight seal to allow for the constant delivery of therapeutics to the ocular surface and surrounding periocular tissue. This study demonstrates the safety and utilization of the OWC on uninjured eyes and in our exposure keratopathy model. For initial safety studies (N = 3 per group), the eyelids remained intact and the eye uninjured. A blepharotomy (N = 6 per group) was performed to remove the upper and lower eyelids surrounding the left (OS) eye to create our exposure keratopathy model. Right (OD) eyes served as uninjured controls in all studies. Following OWC placement, 0.5 mL HPMC gel or balanced saline solution (BSS) was injected into the chamber. Animals were monitored daily and fully assessed via white light, fluorescein, and OCT imaging at least through 72 hours post OWC placement. In studies that included a blepharotomy, skin samples were analyzed by multiplex cytokine analysis. Results of safety experiments revealed no significant differences between treatment groups in corneal thickness, fluorescein staining, OCT imaging, or histological eye or skin sections when compared to control eyes. In our exposure keratopathy model, OWC treated eyes showed significantly less fluorescein uptake and also were found to have significantly lower levels of cytokines IL-13 and IL-5 in skin samples. These results demonstrate for the first time that treatment using the OWC device is not only safe, but significantly protects against blepharotomy-induced exposure keratopathy. As a whole, this study advances our overall efforts to develop a feasible solution to treat ocular surface injuries, infections, and periocular burns.
Preserving the corneal surface is imperative in preventing vision loss in patients suffering from exposure keratopathy. The cornea is responsible for two-thirds of the focusing power of the eye, while the lens focuses the remaining onethird of the refracted light. 1 Together, the cornea and lens play a critical role in vision by focusing refracted light accurately. The actual refraction of light occurs on the corneal surface at the air-tear film interface. In the case of exposure keratopathy, irregularities of the corneal epithelium and adjacent tear film cause refractive heterogeneity of the otherwise smooth optical surface of the cornea. 2, 3 If the corneal surface is not protected by the overlying eyelids, the resultant exposure results in the relentless sequelae of dehydration, corneal swelling, epithelial cell loss, infection, and perforation with loss of the eye. Dry eye patients experience losses in visual acuity by the aforementioned surface irregularity, which affects their ability to drive, read, and operate a computer. 4 As a result, the quality of life in these patients is severely impacted. In the case of trauma patients whose eyelids, for a variety of reasons, fail to protect the ocular surface, the clinical prognosis is much worse and exposure keratopathy can become an immediate and serious issue. The management and rehabilitation of these patients is one of the more difficult aspects of modern medicine due to the potential for long term ocular surface complications, severe vision loss, and disfigurement. 5 Even more problematic is the treatment of patients who also have devastating facial burns that may compromise, not only ocular structures and vision, but also the surrounding periocular tissue. The difficulties faced when treating these patients has left clinicians searching for novel therapeutic interventions.
Current therapies using bandage contact lenses, amniotic membrane placement, tarsorrhaphy (partial suturing of upper and lower eyelids), and surgical reconstruction of the eyelid are designed to provide protection to the compromised ocular surfaces but are frequently inadequate at treating severe ocular burn cases. For example, when amniotic membrane is placed to treat exposure and ocular surface inflammation, it quickly degrades in the highly inflamed eye. 6 Bandage contact lenses and tarsorrhaphy are excluded as treatment options if the patient has limited or seriously compromised lid tissue sufficient to hold the lens in place. Other treatment modalities including eye patches, modified swim goggles, or cellophane wrap used in conjunction with ophthalmic lubricants to create moisture chambers have yielded less than optimal outcomes, especially in severely burned patients. 7 Surgical reconstruction of the eyelids to provide better protection of the ocular surface fail by cicatricial contraction until the periorbital inflammation has abated. Clearly, a simple method for protecting the ocular surface is needed for this special class of patients. It is also possible that protection of the eyelids may limit thermal damage and reduce the amount of cicatricial lagophthalmos resulting from severe burns.
To fulfill this unmet need, we have developed an ocular wound chamber (OWC) device to not only treat the periocular tissues of burn patients, but also prevent exposure keratopathy and the ocular surface. Adapted from a currently available dermal wound chamber, [8] [9] [10] the flexible, transparent ocular chamber attaches to the perimeter of the eye providing protection from the external environment while delivering continuous therapeutics to the injured tissues. The animal model utilized in this study was designed to test the hypothesis that our OWC can be safely applied over the eye and also prevent the development of exposure keratopathy.
MATERIALS AND METHODS

Animals
Female Institute Armand Frappier (IAF) hairless, guinea pigs (200-250 g, Crl:HA-Hr hr ) were purchased from Charles River Laboratories (Wilmington, MA). The guinea pigs were acclimated for a minimum of 72 hours prior to experimentation. Animals were randomly assigned (N = 3-6 per group) for treatment. Prior to all surgical procedures or chamber placement, animals were administered isoflurane titrated to effect (1-3.5%) with 100% oxygen for 2 m before an intraperitoneal injection of ketamine (Ketacine HCl, VetOne, Boise, ID; 20-40 mg/kg) and dexmedetomidine hydrochloride (Putney, Overland Park, KS; 0.5 mg/kg) was given. After procedures were complete, anesthesia was reversed utilizing atipamezole hydrochloride (Orion Pharma, Espoo, Finland; 0.5 mg/kg) at a dose equivalent to the dexmedetomidine previously administered. Buprenorphine SR (lab; Zoopharm, Windsor, CO) was given (0.2 mg/kg) subcutaneously every 72 hours, or more frequently as needed to control pain in animals in which a blepharotomy was performed. Research was conducted in compliance with the Animal Welfare Act, the implementing Animal Welfare Regulations, and the principles of the Guide for the Care and Use of Laboratory Animals, National Research Council. The facility's Institutional Animal Care and Use Committee approved all research conducted in this study. The facility where this research was conducted is fully accredited by AALAC International.
Application of the ocular wound chamber as a treatment
While under anesthesia, excess hair surrounding the left (OS) eye of guinea pigs was removed using a depilatory cream (Nair, Church & Dwight Co., Inc., Ewing, NJ) (30 seconds) followed by liberal rinsing of the area with balanced salt solution (BSS; Alcon, Fort Worth, TX). During hair removal, eyes were protected with Refresh Lacri-Lube (Allergan, Parsippany, NJ). Post hair removal and cleaning of the skin with 70% ethanol, designated guinea pigs fitted with a polyurethane OWC (Applied Tissue Technologies LLC, Hingham, MA) over the left (OS) eye. Either 500 μL of GenTeal gel (Novartis, East Hanover, NJ), referred to hereafter as hydroxypropyl methylcellulose (HPMC) gel, or BSS was injected into the OWC through the self-sealing silicone port using a 25 gauge 1" needle. For biocompatibility testing (N = 3 per group), HPMC gel (Novartis) or BSS was utilized in the OWC and replaced daily after imaging and assessments were performed at 0, 24, and 72 hours post chamber placement. For blepharotomy (N = 6 per group) studies, HPMC gel was used exclusively and was either applied topically or injected into the OWC at 0, 48, and 96 hours after lid removal.
Corneal imaging
White light and fluorescein images were obtained at designated time points post chamber placement utilizing a surgical microscope equipped with a camera and cobalt blue filter (OPMI VISU 200 S8; Carl Zeiss Surgical, Oberkochen, Germany). Wounds were stained using sterile fluorescein sodium ophthalmic films USP (Fluorets, Chauvin Laboratory, Aubenas, France) dampened with 100 μL sterile BSS followed by liberal rinsing of the eye with BSS. Fluorescein uptake was visualized under cobalt blue light and reported as the area of fluorescein uptake.
Optical coherence tomography
Corneal thickness was assessed using optical coherence tomography (OCT) (Micron IV; Phoenix Research Laboratories, Pleasanton, CA). Images were obtained for each animal at scheduled exam times as reported. Central corneal thickness was measured using ImageJ analysis software (NIH, Bethesda, MD).
Blepharotomy
After induction of general anesthesia, the eye and periorbital tissue of the left eye were prepared with a betadine eye preparation solution. A cotton tipped applicator soaked in betadine eye prep solution was used to cleanse the eyelid and periorbital tissue three times. After preparation of the eye and surrounding periorbital tissue, forceps with teeth (#12) were used to grip the upper and lower eyelids. A 25 gauge needle was employed to inject 0.05-0.1 mL of 2% lidocaine HCL with epinephrine 1:100,000 USP (Hospira, Inc., Lake Forest, IL) into the upper and lower eyelid. A blepharotomy was then performed using Westcott scissors by cutting the entire upper and lower lid from the orbital rim. Hemostasis was maintained with a high temperature handheld cautery as needed.
Histology
After humane euthanasia, whole guinea pig eyes and eyelid skin samples were collected for histology. Whole globes were immediately fixed by placing in modified Davidson's solution (Poly Scientific R&D Corporation, Bay Shore, NY) for 24 hours then postfixed in 10% neutral buffered formalin (NBF; Thermo Fisher Scientific, Middletown, VA). Globes were bisected vertically through the wound (when present) and each half placed, cut side down, in a megatissue cassette (Fisher Scientific, Fair Lawn, NJ). Skin samples (to include areas in contact with wound chamber adhesive) were placed in 10% NBF (Thermo Fisher Scientific). All samples were processed, embedded in paraffin, and sectioned at 4 μm and stained with hematoxylin and eosin (H&E; Thermo Fisher Scientific) according to manufacturer's directions. Histological sections were reviewed by a board certified veterinary pathologist.
Cytokine and chemokine expression analysis
Eyelid skin samples were surgically collected from humanely euthanized guinea pigs and flash frozen in liquid nitrogen. Skin sections of equal weight (20 mg) were placed in screw cap RINO tubes (Next Advance, Inc., Troy, NY). Each prepared tube contained equal amounts of 3.5 mm UFO stainless steel beads (Next Advance, Inc.) and 1 mL of MILLIPLEX MAP Lysis buffer (MilliporeSigma, Burlington, MA) with a Sigma Protease Inhibitor Cocktail (MilliporeSigma). Samples were homogenized for 5 m at max speed using the Bullet Blender (Next Advance, Inc.). Homogenates were clarified by centrifugation at 16,873 × g for 5 m at 4 C followed by protein quantification using a bicinchoninic acid assay (BCA) kit (ThermoFisher Scientific, Grand Island, NY) according to the manufacturer's instructions. Samples were analyzed utilizing a MILLIPLEX MAP Mouse Cytokine/Chemokine 32 plex assay (MilliporeSigma) at a 1:5 dilution of sample to buffer in 25 μL total volume. Data was analyzed using Luminex multiplex analysis software (MilliporeSigma) and samples were normalized to BCA-determined protein concentrations.
Statistical analysis
For safety studies, statistics were calculated using JMP 10 software (SAS Institute Inc., Cary, NC) using the Wilcoxon/Kruskal-Wallis method. Blepharotomy studies were calculated using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA) utilizing a repeated-measures two-way analysis of variance (ANOVA) with Bonferroni posttest. All results were graphed using GraphPad Prism. Independent values are demonstrated ± the standard error of mean (SEM). A p-value of < .05 was regarded as significant for all statistical analyses. Figure 1A ) were successfully manufactured for ocular use by Applied Tissue Technologies LLC. The OWC consists of a polyurethane base and removable transparent cover equipped with a self-sealing silicone port ( Figure 1B) . Each OWC was affixed over the left eyes (OS) of the guinea pigs. Either 0.5 mL HPMC gel or BSS was injected via the attached port ( Figure 1B ). Each fluid filled OWC was successfully retained over the eye for at least 24 hours and up to 48 hours.
RESULTS
OWC development, placement, and retention
Ocular wound chambers 3 cm in diameter (
OWC use on an uninjured eye
To determine the effects of placing the eye in a fluid filled environment for a long period of time, all animals were observed clinically via white light and fluorescein staining before the chamber was placed at 0 hour as well as at defined exam time points post chamber placement. Analysis of fluorescein uptake staining was employed to identify any defects in the corneal epithelium. White light (Figure 2A ) and fluorescein imaging ( Figure 2B ) studies did not reveal any changes in the ocular surface or epithelial defects in biocompatibility studies as a result of chamber use with either HPMC gel or BSS treatment when compared to controls.
The effect of OWC use on corneal thickness in an uninjured model
To ensure that continuous fluid exposure would not cause the cornea to swell, ophthalmic imaging was conducted in conjunction with other traditional, clinical testing including the measurement of the corneal thickness via optical coherence tomography (Figure 3) . At each time point, corneal thickness ( Figure 3 A and B) of the eyes fitted with the filled chambers (OS) and the control eyes (OD) were measured. Results revealed the average corneal thickness of the guinea pig to be approximately 181 ± 13 μm at 0 hour before treatment. By 24 hours, the average thickness per group was 203 ± 7 μm, 206 ± 20 μm, and 217± 3 μm for nontreated control eyes and HPMC gel and BSS treated eyes respectively. At the end of the study, control eyes remained around 207 ± 13 μm while HPMC gel treated eyes were 176 ± 3 μm and BSS treated corneas remained around 197 ± 11 μm. Overall, these results show that an average guinea pig cornea is approximately 181 μm thick and corneal thickness does not significantly change compared to controls when a noninjured cornea is covered in a gel or fluid via the OWC for 72 hours.
OWC treated tissue histology
Whole eye globes and eyelid skin samples were collected at the conclusion of the study (72 hours) and sent for histological processing to ensure no pathological changes were induced by the OWC or treatments. Corneal and eyelid sections were stained with H&E and reviewed by a masked veterinary pathologist. The analysis of corneal surface histology ( Figure 4A ) revealed no pathological signs in either the treatment or control groups for neovascularization, corneal epithelial thinning, and corneal edema. Analysis of eyelid samples also revealed no pathological findings associated with OWC use. The cutaneous surface (outer skin) ( Figure 4B ) and the conjunctival surface (inner surface facing the eye) of the eyelid were also reviewed and no pathology or inflammation was observed. 
OWC use prevents the formation of corneal defects
To determine the effectiveness of the OWC on preventing exposure keratopathy, a blepharotomy model was developed. Just prior to and following removal of the upper and lower eyelids, white and cobalt blue light images were obtained at 0, 48, and 96 hours. White light images ( Figure 5A ) revealed areas of corneal opacity in eyes of animals that were not treated with a chamber versus those that received treatment with an OWC. Images of fluorescein uptake ( Figure 5B ) revealed a significant, time related ( Figure 5C ) increase in fluorescein uptake in animals that were not treated with an OWC when compared to those that received an OWC. Overall, our results revealed that OWC placement prevented the formation of ocular surface defects through 96 hours as illustrated by the significant increase ( Figure 5C ) in fluorescein uptake in animals that did not receive an OWC.
The effect of OWC use on corneal swelling in an exposure keratopathy model As stated above, corneal thickness was observed via OCT imaging at 0, 48, and 96 hours ( Figure 6A ). Corneal thickness was measured through the central cornea at each time point to investigate any changes in corneal thickness as a result of treatment. No significant differences were observed between the eyes treated with an OWC and those that were not treated with an OWC in our exposure keratopathy model ( Figure 6B ). These results indicate that treatment with an OWC does not affect corneal thickness in our model.
Treatment with an OWC modulates cytokines in the skin
The levels of cytokines and chemokines in the periocular skin tissue ( Figure 7A ) were assessed using a multiplex protein assay. Results show IL-13 and IL-5 were significantly lower in skin samples from animals that were treated with the OWC (IL-13: 80.39 pg/mL; IL-5: 44.87 pg/mL) when compared to untreated skin samples (IL-13: 146.127 pg/mL; IL-5: 104.374 pg/mL).
DISCUSSION
In this study, we investigated the use of our OWC device on uninjured eyes before moving to a more advanced model of exposure keratopathy. Our initial studies tested the ability of the OWC to maintain a moisture rich environment over an uninjured eye when the chamber was filled with either HPMC gel or BSS. Results from these initial studies demonstrated the OWC is biocompatible with the ocular surface of an intact eye and caused no significant changes in corneal thickness when compared to controls. Furthermore, the analysis of histological samples taken from uninjured eyes and skin samples treated with the OWC revealed that treatment with BSS or HPMC gel did not result in corneal inflammation suggesting both treatments are equally compatible with uninjured tissues. These results indicate that the OWC is safe on both an uninjured ocular surface as well as uninjured skin. Following the success of our initial studies, we sought to determine the utility and effectiveness of the OWC for both the prevention of exposure keratopathy and the treatment of injured periorbital tissue in a more complex model.
In our exposure keratopathy model, the OWC device was placed over the eye of the guinea pig and loaded with HPMC gel following eyelid removal. Treatment with the OWC completely prevented the formation of exposure keratopathy as indicated by the lack of fluorescein staining in animals treated with an OWC. Additionally, no significant differences in corneal thickness between treatment groups were observed. This lends further support for the potential to use this device to prevent exposure keratopathy in patients with little or no eyelids available to cover the eye. Given the protection provided to the ocular surface in this injury model using the OWC, we also sought to observe the effects of the OWC on injured skin.
Studies conducted on burn injuries have illustrated that wounds heal more efficiently in a moist environment. 9, [11] [12] [13] Previously published studies have shown that utilization of a platform wound device (PWD), from which the OWC is based, results in more favorable clinical outcomes and can decrease the amount of fibrosis in wounds.
14 Per Junker . Statistical comparisons were performed using a student's t test between groups. These data are representative of 6 animals per group. ** p < .005; *** p < .0005.
et al., the wound healing environment is defined as dry when there is no aqueous barrier over the wound, moist when the wound is covered with a controlled dressing provided hydration, and wet when the wound is covered by an impermeable wound dressing and sealed with adhesives. 8 In the case of the wound chamber, the OWC provides a wet dressing to hydrate the eye as well as protect the eyelids. Cytokine and chemokine analysis was performed on skin samples and whole, excised corneas. No differences in the cytokine profile were seen in the corneal samples. However, OWC treated, injured skin samples (harvested from the area proximal to the eyelid removal zone) had significantly lower levels of the fibrosis associated cytokines IL-13 and IL-5 15 when compared to untreated, injured skin sample controls. While further studies will be needed to entirely elucidate this mechanism and how this affects the healing of the skin, the modulation of these cytokines suggests that the OWC appears to alter the wound healing environment. This may result in more optimal would healing of the skin as observed in previous studies using the PWD.
In conclusion, these preclinical studies indicate that the OWC may be a safe, suitable, and effective device to treat and prevent exposure keratopathy patients. Additionally, we showed the ability of the OWC to deliver specific volumes and concentrations of therapeutics to the surface of the eye and surrounding tissues in a sustained and controlled manner. Taken together, the results from these studies illustrate the potential of the OWC to improve patient outcomes for those suffering from exposure keratopathy and may be particularly well-suited to treat burn patients with severely damaged periorbital tissue. Future studies will test the OWC in conjunction with candidate therapeutics in a corneal infection model.
